Vringo’s NDA dispute with ZTE has been previously noted in this blog. The case in the Southern District of New York involved violation of a Non-Disclosure Agreement by alleging revealing confidential materials […]
CFDA’s New Policies to Promote IP and Innovation in the Pharma Sector
As noted previously in this blog, the death of patent linkage which had been heralded by draft Drug Registration Rules appears to be premature. In fact, the China Food and Drug Administration […]
SPC Puts National Appellate IP Court On Its Agenda
At an IP symposium held this Wednesday, May 10, 2017 in Chengdu, it was revealed by a senior Chinese academic (Prof. Wu Handong) in response to a question raised by former Chief Judge Randall […]